

Marketing Moratorium Set on 7 Advantage Plans

BY MARY ELLEN SCHNEIDER
New York Bureau

Several Medicare Advantage fee-for-service plan sponsors have agreed to voluntarily suspend marketing of their plans until officials at the Centers for Medicare and Medicaid Services can verify that they are in compliance with certain management controls.

CMS officials announced this temporary marketing moratorium as part of an effort

to halt deceptive marketing practices in the private fee-for-service Medicare market.

"It is our strong belief that while most agents and brokers are helpful and responsible in describing and explaining choices to beneficiaries, there are a few bad actors operating in the marketplace that need to be removed from the system," Abby Block, director of the Center for Beneficiary Choices at the CMS, said during a press briefing. "This voluntary agreement demonstrates that the plans are step-

ping up to ensure that deceptive marketing practices end and that beneficiaries fully understand what they are purchasing."

From last December through April, CMS officials received about 2,700 complaints from beneficiaries regarding Medicare Advantage plans, with many of those complaints relating to private fee-for-service plans.

However, Ms. Block pointed out that the 2,700 complaints account for a small fraction of the 1.3 million Medicare ben-

eficiaries who have elected to enroll in such plans.

The problems reported range from agents encouraging the misperception that the private plans are just like traditional Medicare and are accepted by all providers who accept Medicare to more blatant cases of deception in which agents have told beneficiaries they are still enrolled in traditional Medicare and are purchasing a Medigap supplemental insurance policy.

The seven private fee-for-service Medicare plans that recently signed an agreement with the CMS to suspend their marketing efforts are United Healthcare, Humana, WellCare, Universal American Financial Corporation (Pyramid), Coventry, Sterling, and Blue Cross Blue Shield of Tennessee. Together, they account for about 90% of enrollment in private fee-for-service plans, according to the CMS. "These are clearly the major players in the industry," Ms. Block said.

The plans were not singled out because of particular problems with their market-

ing practices, Ms. Block said. The real concern relates to actions by a small number of rogue brokers and agents with whom these and other organizations may contract, she said. The temporary moratorium does not apply to enrollment among the plans and does not affect the employer market, where CMS has not received complaints of issues with marketing tactics.

The marketing moratorium will be lifted on a plan-by-plan basis when the CMS certifies that the plan has both systems and management controls in place that meet conditions spelled out by the agency in guidance earlier this year.

For example, plan sponsors will have to show that all of their advertising, marketing, and enrollment materials include model disclaimer language provided by the CMS that private fee-for-service Medicare plans are not the same as traditional Medicare or Medigap and that not all providers will accept the plan. All representatives selling products on behalf of a plan sponsor will have to pass a written test demonstrating familiarity with Medicare and fee-for-service plans.

Plans must also agree to provide a list of individuals who are marketing the plan upon request by the CMS or state agencies. The CMS will begin to review plans as soon as they indicate they are in compliance, Ms. Block said.

In addition, the CMS will be monitoring all private fee-for-service plans to ensure they are not engaging in deceptive marketing practices. "We will be watching very carefully as the entire industry begins marketing in October for the 2008 benefit year," Ms. Block said. ■

Boston University School of Medicine
and

Pediatric News / Family Practice News

JOINTLY SPONSOR

Pediatric Infectious Diseases in the Headlines

A Continuing Medical Education Conference

November 2 – 3, 2007

Hotel Marlowe, Cambridge, MA

Topic Highlights

Influenza: Treatment and Prevention

Mycoplasma and Chlamydia: Role in Pediatric Respiratory Illness Revisited

Urinary Tract Infection in Children: Lessons from Clinical Trials

Staphylococcal Infections: Current Treatment and Prevention

Travel Medicine: What's New for the Primary Care Setting

Universal HIV Testing in Children and Adolescents

Serious Infections of the Head and Neck

Tuberculosis

Acute Otitis Media: Can We Agree?

Indirect Protection From Vaccines: Getting More Efficacy for Each Dose

Pediatric Infectious Diseases in the News

Advances in Pediatric ID: Relevance to the Office Practice

Adolescent Immunizations

The Infectious Disease Health of Health Care Workers

Vaccine Safety

Infectious Disease and Immunization Issues Before and After International Adoption

Managing STDs in Office Practice

Clinical Implications of Antibiotic Resistance/Presumptive Antibiotic Therapy for Common Pediatric Infectious Diseases (Otitis, CAP, Sinusitis)

Target Audience: This conference is designed for pediatricians, infectious disease specialists, family practitioners, nurse practitioners, and physician assistants.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Pediatric News/Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of **12.75 AMA PRA Category 1 Credit(s)**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Application for CME credit has been filed with the American Academy of Family Physicians. **Determination of credit is pending.**

Educational Objectives: At the conclusion of this conference, participants will be able to:

- Discuss the latest modalities of treatment for bacterial and viral infections
- List current recommendations for immunizations of all pediatric ages, including infants and adolescents
- Identify best practices for the treatment of such pediatric infectious diseases as acute otitis media, sexually transmitted infections, and influenza

Register Now!



Course Directors

Jerome O. Klein, M.D.
Professor of Pediatrics

Stephen I. Pelton, M.D.
Professor of Pediatrics
Chief, Division of Pediatric Infectious Diseases

Guest Faculty

Alejandro Hoberman, M.D.
Chief, Division of General Academic Pediatrics
Professor of Pediatrics
Jack L. Paradise Professor of Pediatric Research
Children's Hospital of Pittsburgh

Boston University School of Medicine Faculty

Elizabeth D. Barnett, M.D.
Associate Professor of Pediatrics

Howard Bauchner, M.D.
Professor of Pediatrics and Public Health
Director, Division of General Pediatrics

Ellen R. Cooper, M.D.
Associate Professor of Pediatrics

Estella Escobar, M.D.
Fellow, Division of Pediatric Infectious Diseases

Marisol Figueira, M.D.
Assistant Professor of Pediatrics

Katherine Hsu, M.D.
Assistant Professor of Pediatrics

Colin D. Marchant, M.D.
Associate Professor of Pediatrics

Vishakha Sabharwal, M.D.
Fellow, Division of Pediatric Infectious Diseases

Carolina Sanchez-Vegas, M.D.
Fellow, Division of Pediatric Infectious Diseases



To register, please contact:

**Office of Continuing Medical Education
Boston University School of Medicine**

715 Albany Street, A305
Boston, MA, 02118

Phone: (617) 638-4605

Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: cme@bu.edu

Website: <http://www.bu.edu/cme>